Feed 6160.HK
61

BeOne Medicines AG

6160.HK · HKSE

$211.20 -3.74% (-$8.20)
1M +10.29%
Market Cap $35.8B
P/E Ratio 124.69x
Div. Yield -
ROE 7.11%

Bulios Fair Price

$242.65

14.9% upside

Current Price

$211.2

Undervalued Fair Value Overvalued

According to Bulios Fair Price, 6160.HK is currently undervalued relative to its market price. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
10 /100
Expensive
P/E 124.69x
EV/EBITDA 54.84x
P/S 6.70x
Growth
83 /100
Growing
Rev. growth 55.76%
Book val. growth 0.17%
EPS growth N/A
Profitability
68 /100
Strong
Gross margin 85.28%
Net margin 5.37%
Op. margin 8.37%
Quality
33 /100
Poor
ROIC 4.78%
ROE 7.11%
ROA 3.49%
Debt
95 /100
Low
Debt/Equity 0.25x
Current ratio 3.41x
Int. coverage 7.68x
Stability
49 /100
Moderate
Beta 0.50x
Rev. volatility 16.65%
EPS volatility 59.78%
Ask StockBot about 6160.HK
Online

Sector

Healthcare

Industry

Biotechnology

CEO

John V. Oyler

Employees

12,000

Headquarters

Basel

Upcoming events

05 NOV

Earnings

Upcoming earnings report

80d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.